Biologics Market Size, Share & Trends Report

Biologics Market Size, Share & Trends Analysis Report By Source (Microbial, Mammalian), By Products (Monoclonal Antibodies, Vaccines, Recombinant Proteins, Antisense, RNAi), By Disease Category, By Manufacturing, And Segment Forecasts, 2020 - 2025

  • Report ID: GVR-1-68038-700-1
  • Number of Pages: 185
  • Format: Electronic (PDF)
  • Historical Range: 2014 - 2018
  • Industry: Healthcare

Market Segmentation

  • Biologics Source Outlook (Revenue, USD Billion, 2014 - 2025)
    • Microbial
    • Mammalian
    • Others
  • Biologics Product Outlook (Revenue, USD Billion, 2014 - 2025)
    • MABs
      • By Application
        • Diagnostic
          • Biochemical Analysis
          • Diagnostic Imaging
        • Therapeutic
          • Direct MAB Agents
          • Targeting MAB Agents
        • Protein Purification
        • Others
      • By Type
        • Murine
        • Chimeric
        • Humanized
        • Human
        • Others
    • Vaccines
    • Recombinant Proteins
    • Antisense, RNAi, & Molecular Therapy
    • Others
  • Biologics Disease Category Outlook (Revenue, USD Billion, 2014 - 2025)
    • Oncology
      • By Product
        • MABs
        • Vaccines
        • Recombinant Proteins
        • Antisense, RNAi, & Molecular Therapy
        • Others (Certain products under trials related to blood products etc)
        • Infectious Diseases
      • By Product
        • Vaccines
        • MABs
        • Antisense, RNAi, & Molecular Therapy
        • Recombinant Proteins
        • Others
    • Immunological Disorders
    • Cardiovascular Disorders
    • Hematological Disorders
    • Others
  • Biologics Manufacturing Outlook (Revenue, USD Billion, 2014 - 2025)
    • Outsourced
    • In-house
  • Biologics Regional Outlook (Revenue, USD Billion, 2014 - 2025)
    • North America
      • The U.S.
        • The U.S. Source Outlook (Revenue, USD Billion, 2014 - 2025)
          • Microbial
          • Mammalian
          • Others
        • The U.S. Product Outlook (Revenue, USD Billion, 2014 - 2025)
          • MABs
            • By Application
              • Diagnostic
                • Biochemical Analysis
                • Diagnostic Imaging
              • Therapeutic
                • Direct MAB Agents
                • Targeting MAB Agents
              • Protein Purification
              • Others
            • By Type
              • Murine
              • Chimeric
              • Humanized
              • Human
              • Others
          • Vaccines
          • Recombinant Proteins
          • Antisense, RNAi, & Molecular Therapy
          • Others
        • The U.S. Manufacturing Outlook (Revenue, USD Billion, 2014 - 2025)
          • Outsourced
          • In-house
        • The U.S. Disease Category Outlook (Revenue, USD Billion, 2014 - 2025)
          • Oncology
            • By Product
              • MABs
              • Vaccines
              • Recombinant Proteins
              • Antisense, RNAi, & Molecular Therapy
              • Others (Certain products under trials related to blood products etc)
              • Infectious Diseases
            • By Product
              • Vaccines
              • MABs
              • Antisense, RNAi, & Molecular Therapy
              • Recombinant Proteins
              • Others
          • Immunological Disorders
          • Cardiovascular Disorders
          • Hematological Disorders
          • Others
      • Canada
        • Canada Source Outlook (Revenue, USD Billion, 2014 - 2025)
          • Microbial
          • Mammalian
          • Others
        • Canada Product Outlook (Revenue, USD Billion, 2014 - 2025)
          • MABs
            • By Application
              • Diagnostic
                • Biochemical Analysis
                • Diagnostic Imaging
              • Therapeutic
                • Direct MAB Agents
                • Targeting MAB Agents
              • Protein Purification
              • Others
            • By Type
              • Murine
              • Chimeric
              • Humanized
              • Human
              • Others
          • Vaccines
          • Recombinant Proteins
          • Antisense, RNAi, & Molecular Therapy
          • Others
        • Canada Manufacturing Outlook (Revenue, USD Billion, 2014 - 2025)
          • Outsourced
          • In-house
        • Canada Disease Category Outlook (Revenue, USD Billion, 2014 - 2025)
          • Oncology
            • By Product
              • MABs
              • Vaccines
              • Recombinant Proteins
              • Antisense, RNAi, & Molecular Therapy
              • Others (Certain products under trials related to blood products etc)
              • Infectious Diseases
            • By Product
              • Vaccines
              • MABs
              • Antisense, RNAi, & Molecular Therapy
              • Recombinant Proteins
              • Others
          • Immunological Disorders
          • Cardiovascular Disorders
          • Hematological Disorders
          • Others
    • Europe
      • Germany
        • Germany Source Outlook (Revenue, USD Billion, 2014 - 2025)
          • Microbial
          • Mammalian
          • Others
        • Germany Product Outlook (Revenue, USD Billion, 2014 - 2025)
          • MABs
            • By Application
              • Diagnostic
                • Biochemical Analysis
                • Diagnostic Imaging
              • Therapeutic
                • Direct MAB Agents
                • Targeting MAB Agents
              • Protein Purification
              • Others
            • By Type
              • Murine
              • Chimeric
              • Humanized
              • Human
              • Others
          • Vaccines
          • Recombinant Proteins
          • Antisense, RNAi, & Molecular Therapy
          • Others
        • Germany Manufacturing Outlook (Revenue, USD Billion, 2014 - 2025)
          • Outsourced
          • In-house
        • Germany Disease Category Outlook (Revenue, USD Billion, 2014 - 2025)
          • Oncology
            • By Product
              • MABs
              • Vaccines
              • Recombinant Proteins
              • Antisense, RNAi, & Molecular Therapy
              • Others (Certain products under trials related to blood products etc)
              • Infectious Diseases
            • By Product
              • Vaccines
              • MABs
              • Antisense, RNAi, & Molecular Therapy
              • Recombinant Proteins
              • Others
          • Immunological Disorders
          • Cardiovascular Disorders
          • Hematological Disorders
          • Others
      •  The U.K.
        • The U.K. Source Outlook (Revenue, USD Billion, 2014 - 2025)
          • Microbial
          • Mammalian
          • Others
        • The U.K. Product Outlook (Revenue, USD Billion, 2014 - 2025)
          • MABs
            • By Application
              • Diagnostic
                • Biochemical Analysis
                • Diagnostic Imaging
              • Therapeutic
                • Direct MAB Agents
                • Targeting MAB Agents
              • Protein Purification
              • Others
            • By Type
              • Murine
              • Chimeric
              • Humanized
              • Human
              • Others
          • Vaccines
          • Recombinant Proteins
          • Antisense, RNAi, & Molecular Therapy
          • Others
        • UK Manufacturing Outlook (Revenue, USD Billion, 2014 - 2025)
          • Outsourced
          • In-house
        • UK Disease Category Outlook (Revenue, USD Billion, 2014 - 2025)
          • Oncology
            • By Product
              • MABs
              • Vaccines
              • Recombinant Proteins
              • Antisense, RNAi, & Molecular Therapy
              • Others (Certain products under trials related to blood products etc)
              • Infectious Diseases
            • By Product
              • Vaccines
              • MABs
              • Antisense, RNAi, & Molecular Therapy
              • Recombinant Proteins
              • Others
          • Immunological Disorders
          • Cardiovascular Disorders
          • Hematological Disorders
          • Others
    • Asia Pacific
      •  Japan
        • Japan Source Outlook (Revenue, USD Billion, 2014 - 2025)
          • Microbial
          • Mammalian
          • Others
        • Japan Product Outlook (Revenue, USD Billion, 2014 - 2025)
          • MABs
            • By Application
              • Diagnostic
                • Biochemical Analysis
                • Diagnostic Imaging
              • Therapeutic
                • Direct MAB Agents
                • Targeting MAB Agents
              • Protein Purification
              • Others
            • By Type
              • Murine
              • Chimeric
              • Humanized
              • Human
              • Others
          • Vaccines
          • Recombinant Proteins
          • Antisense, RNAi, & Molecular Therapy
          • Others
        • Japan Manufacturing Outlook (Revenue, USD Billion, 2014 - 2025)
          • Outsourced
          • In-house
        • Japan Disease Category Outlook (Revenue, USD Billion, 2014 - 2025)
          • Oncology
            • By Product
              • MABs
              • Vaccines
              • Recombinant Proteins
              • Antisense, RNAi, & Molecular Therapy
              • Others (Certain products under trials related to blood products etc)
              • Infectious Diseases
            • By Product
              • Vaccines
              • MABs
              • Antisense, RNAi, & Molecular Therapy
              • Recombinant Proteins
              • Others
          • Immunological Disorders
          • Cardiovascular Disorders
          • Hematological Disorders
          • Others
      • China
        • China Source Outlook (Revenue, USD Billion, 2014 - 2025)
          • Microbial
          • Mammalian
          • Others
        • China Product Outlook (Revenue, USD Billion, 2014 - 2025)
          • MABs
            • By Application
              • Diagnostic
                • Biochemical Analysis
                • Diagnostic Imaging
              • Therapeutic
                • Direct MAB Agents
                • Targeting MAB Agents
              • Protein Purification
              • Others
            • By Type
              • Murine
              • Chimeric
              • Humanized
              • Human
              • Others
          • Vaccines
          • Recombinant Proteins
          • Antisense, RNAi, & Molecular Therapy
          • Others
        • China Manufacturing Outlook (Revenue, USD Billion, 2014 - 2025)
          • Outsourced
          • In-house
        • China Disease Category Outlook (Revenue, USD Billion, 2014 - 2025)
          • Oncology
            • By Product
              • MABs
              • Vaccines
              • Recombinant Proteins
              • Antisense, RNAi, & Molecular Therapy
              • Others (Certain products under trials related to blood products etc)
              • Infectious Diseases
            • By Product
              • Vaccines
              • MABs
              • Antisense, RNAi, & Molecular Therapy
              • Recombinant Proteins
              • Others
          • Immunological Disorders
          • Cardiovascular Disorders
          • Hematological Disorders
          • Others
    • Latin America
      •  Brazil
        • Brazil Source Outlook (Revenue, USD Billion, 2014 - 2025)
          • Microbial
          • Mammalian
          • Others
        • Brazil Product Outlook (Revenue, USD Billion, 2014 - 2025)
          • MABs
            • By Application
              • Diagnostic
                • Biochemical Analysis
                • Diagnostic Imaging
              • Therapeutic
                • Direct MAB Agents
                • Targeting MAB Agents
              • Protein Purification
              • Others
            • By Type
              • Murine
              • Chimeric
              • Humanized
              • Human
              • Others
          • Vaccines
          • Recombinant Proteins
          • Antisense, RNAi, & Molecular Therapy
          • Others
        • Brazil Manufacturing Outlook (Revenue, USD Billion, 2014 - 2025)
          • Outsourced
          • In-house
        • Brazil Disease Category Outlook (Revenue, USD Billion, 2014 - 2025)
          • Oncology
            • By Product
              • MABs
              • Vaccines
              • Recombinant Proteins
              • Antisense, RNAi, & Molecular Therapy
              • Others (Certain products under trials related to blood products etc)
              • Infectious Diseases
            • By Product
              • Vaccines
              • MABs
              • Antisense, RNAi, & Molecular Therapy
              • Recombinant Proteins
              • Others
          • Immunological Disorders
          • Cardiovascular Disorders
          • Hematological Disorders
          • Others
    • MEA
      •  South Africa
        • South Africa Source Outlook (Revenue, USD Billion, 2014 - 2025)
          • Microbial
          • Mammalian
          • Others
        • South Africa Product Outlook (Revenue, USD Billion, 2014 - 2025)
          • MABs
            • By Application
              • Diagnostic
                • Biochemical Analysis
                • Diagnostic Imaging
              • Therapeutic
                • Direct MAB Agents
                • Targeting MAB Agents
              • Protein Purification
              • Others
            • By Type
              • Murine
              • Chimeric
              • Humanized
              • Human
              • Others
          • Vaccines
          • Recombinant Proteins
          • Antisense, RNAi, & Molecular Therapy
          • Others
        • South Africa Manufacturing Outlook (Revenue, USD Billion, 2014 - 2025)
          • Outsourced
          • In-house
        • South Africa Disease Category Outlook (Revenue, USD Billion, 2014 - 2025)
          • Oncology
            • By Product
              • MABs
              • Vaccines
              • Recombinant Proteins
              • Antisense, RNAi, & Molecular Therapy
              • Others (Certain products under trials related to blood products etc)
              • Infectious Diseases
            • By Product
              • Vaccines
              • MABs
              • Antisense, RNAi, & Molecular Therapy
              • Recombinant Proteins
              • Others
          • Immunological Disorders
          • Cardiovascular Disorders
          • Hematological Disorders
          • Others

Report content

Qualitative Analysis

  • Industry overview
  • Industry trends
  • Market drivers and restraints
  • Market size
  • Growth prospects
  • Porter’s analysis
  • PESTEL analysis
  • Key market opportunities prioritized
  • Competitive landscape
    • Company overview
    • Financial performance
    • Product benchmarking
    • Latest strategic developments

Quantitative Analysis

  • Market size, estimates, and forecast from 2014 to 2025
  • Market estimates and forecast for product segments up to 2025
  • Regional market size and forecast for product segments up to 2025
  • Market estimates and forecast for application segments up to 2025
  • Regional market size and forecast for application segments up to 2025
  • Company financial performance
What questions do you have? Get quick response from our industry experts. Request a Free Consultation
pdf

GET A FREE SAMPLE

bck

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

cog

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

esomar icon

ESOMAR certified & member

D&B icon

Leading SME award by D&B

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.